类风湿关节炎免疫吸附剂的临床应用

目的　探讨免疫吸附剂治疗类风湿关节炎 (RA)的临床效果。方法　将 6 7例RA患者随机分为RA免疫吸附剂治疗 35例 (治疗组 )和非吸附治疗 32例 (对照组 )。将治疗组患者动脉血流经RA免疫吸附剂 ,吸附后由肘静脉回输入体内。随访 8～ 30个月 ,比较两组疗效。结果　治疗组经 1～ 2次吸附治疗 ,有效率 97% (34/ 35 ) ,较对照组 6 9% (2 2 / 32 )差异有显著性 (P <0 0 1)。完全缓解率治疗组 83% (2 9/ 35 ) ,较对照组 5 0 % (16 / 32 )差异有显著性 (P <0 0 1)。其中病史 <2年并关节功能状态Ⅱ级者 2 2例 ,完全缓解率 10 0 % (2 2 / 2 2 ) ,较对照组病史 <2年并关节功能状态Ⅱ级者 2 0例 ,完全缓解率 70 % (14 / 2 0 )差异有显著性 (P <0 0 1)。病史≥ 2年治疗组完全缓解率 5 4 %(7/ 13) ,较对照组 17% (2 / 12 )差异有显著性 (P <0 0 1)。关节功能状态Ⅲ级者治疗组完全缓解率 5 8% (7/ 12 ) ,较对照组 18% (2 / 11)差异有显著性 (P <0 0 1)。结论　免疫吸附剂治疗RA ,优于非吸附疗法

Clinical application of DNA immunoadsorbent for rheumatoid arthritis

Objective Study the clinical outcomes of DNA immunoadsorbent therapy for rheumatoid arthritis (RA).Methods Sixty seven patients were put into DNA immunoadsorbent group (35 cases therapy group)and routine therapy group (32 cases control group) randomly.Made arterial blood of RA patients run through the immunoadsorbent and go back the body via vein.After a follow up of 8～30 months,analyzed the clinical outcomes of the two groups.Results Through 1 or 2 times of adsorption,the therapy group had an effective rate 97%,and a total remission rate 83%;while 69% and 50% correspondingly in control group,a significant difference existed between them( P <0 01).As to the complete remission rate,it was 100% for patients with an under two year history and a Ⅱ grade joint function,53% for those with a two year or over history,58 3% for those with Ⅲ grade joint function in the test group,while correspondingly 70%,17%,18% in the control group.They all had signifi cant difference( P <0 01) respectively.Conclusion Treating RA with RA immunoadsorbent is more effective than routine therapy.